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tomatidine, a natural steroidal 
alkaloid shows antiviral activity 
towards chikungunya virus in vitro
Berit troost1, Lianne M. Mulder1, Mayra Diosa-toro  1,2, Denise van de pol1, 
izabela A. Rodenhuis-Zybert1 & Jolanda M. Smit1*
in recent decades, chikungunya virus (cHiKV) has re-emerged, leading to outbreaks of chikungunya 
fever in Africa, Asia and central and South America. the disease is characterized by a rapid onset febrile 
illness with (poly)arthralgia, myalgia, rashes, headaches and nausea. In 30 to 40% of the cases, CHIKV 
infection causes persistent (poly)arthralgia, lasting for months or even years after initial infection. 
Despite the drastic re-emergence and clinical impact there is no vaccine nor antiviral compound available 
to prevent or control cHiKV infection. Here, we evaluated the antiviral potential of tomatidine towards 
cHiKV infection. We demonstrate that tomatidine potently inhibits virus particle production of multiple 
CHIKV strains. Time-of -addition experiments in Huh7 cells revealed that tomatidine acts at a post-entry 
step of the virus replication cycle. furthermore, a marked decrease in the number of cHiKV-infected cells 
was seen, suggesting that tomatidine predominantly acts early in infection yet after virus attachment 
and cell entry. Antiviral activity was still detected at 24 hours post-infection, indicating that tomatidine 
controls multiple rounds of cHiKV replication. Solasodine and sarsasapogenin, two structural derivatives 
of tomatidine, also showed strong albeit less potent antiviral activity towards cHiKV. in conclusion, this 
study identifies tomatidine as a novel compound to combat CHIKV infection in vitro.
Chikungunya virus (CHIKV) was first identified in Tanzania between 1952 and 1953, where it caused an outbreak 
of chikungunya fever described as febrile polyarthralgia1. Within the last decade, CHIKV re-emerged and caused 
various large outbreaks in Africa, Asia and Central and South America2,3. Among those was an explosive epi-
demic on the Indian Ocean island of La Reunion, where over 266.000 people were affected4. Furthermore, since 
its introduction in the Americas in 2013, CHIKV has spread to over 45 countries in Central and South America 
causing more than 1.7 million infections5.
CHIKV is transmitted to humans via the mosquito vectors Aedes aegypti and Aedes albopictus6. Important 
reasons for the drastic re-emergence of CHIKV is the expansion of the mosquito vector to urban areas with poor 
hygiene conditions, progressing climate change as well as the continuous increase in global transportation sys-
tems7. While other mosquito-borne arboviruses, such as dengue virus (DENV), only cause symptoms in a small 
fraction of infected individuals, CHIKV infection causes clinical manifestations in approximately 85% of infected 
individuals8. Acute chikungunya fever typically manifests as a rapid-onset illness characterized by fever, (poly)
arthralgia, myalgia, maculopapular rashes, headaches and nausea9. Notably, 30 to 40% of patients suffer from 
persistent (poly)arthralgia that develops after clearance of the virus10. Appropriately, chikungunya in the African 
Makonde language translates as “that which bends up”, referring to the debilitating joint pain patients often expe-
rience upon CHIKV infection6.
To date, the development of an effective treatment for CHIKV infection has not been successful. While various 
studies reported the development of CHIKV vaccine candidates and antiviral compounds in vitro and in animal 
models, there is no licensed vaccine or therapeutic available to prevent or treat CHIKV infection6,11–13. To combat 
CHIKV, we therefore currently rely on personal protective measures and vector control. The limited resources to 
control CHIKV infection and the rapid re-emergence emphasize the importance of identifying new compounds 
that effectively prevent or control CHIKV infection.
Tomatidine is a steroidal alkaloid derived from the stem and leaves of unripe, green tomatoes. It has been 
described to exhibit a variety of health-beneficial biological activities, including anti-metastatic activity14, 
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anti-inflammatory activity15, anti-microbial activity16–18, and was shown to have a protective effect against 
age-related muscle atrophy19. Tomatidine was also found to exhibit antiviral activity towards the plant viruses 
Sunnhemp Rosette and Tobacco mosaic virus20. We recently identified tomatidine as a novel antiviral compound 
towards two re-emerging mosquito-borne flaviviruses: dengue virus (DENV) and zika virus (ZIKV)21. Potent 
antiviral activity was seen for all four DENV serotypes and a recent isolate of ZIKV. The most potent effect was 
seen for DENV serotype 2, with a half maximal effective concentration (EC50) of 0.82 µM. Tomatidine was 
shown to interfere with various stages of the viral replication cycle of DENV, yet predominantly after virus cell 
binding and internalization. No antiviral activity was observed for West Nile virus (WNV), a closely related 
mosquito-borne flavivirus.
Here, we evaluated the antiviral potential of tomatidine towards three different lineages of CHIKV, the East/
Central/South African lineage, the original African isolate from 1953 as well as Asian lineage. We observed potent 
antiviral activity of tomatidine towards the three different CHIKV strains in Huh7 cells, with EC50 and EC90 
values between 1.2 µM and 3.8 µM, respectively. Antiviral activity was also observed in Vero-WHO, HFF-1 and 
U2OS cells. In contrast to DENV, antiviral activity towards CHIKV was specifically seen at post-infection condi-
tions. Tomatidine drastically reduced the number of infected cells and lead to an overall reduction in the num-
ber of produced progeny virions. Importantly, its antiviral activity was still observed at 24 hours post-infection, 
indicating that tomatidine effectively controls at least three rounds of CHIKV replication and highlighting its 
potential as an antiviral compound to treat CHIKV.
Results
tomatidine inhibits cHiKV infection in various cell lines. First, we tested the antiviral effect of toma-
tidine on CHIKV in Vero-WHO cells, as these cells are highly permissive to infection and are often used in 
related studies6,22–24. Prior to the infection experiments, the cytotoxic profile of tomatidine in Vero-WHO cells 
was determined via an ATPLite assay. As shown in Supplementary Fig. S1a, tomatidine induced a dose-dependent 
reduction in ATP level with a CC50 value of 149 µM. The CC50 value represents the concentration of tomatidine 
needed to decrease the ATP level of the cells by 50%. The highest non-toxic tomatidine concentration (defined 
by survival rates above 75%) was 10 µM (Supplementary Fig. S1a) and was therefore used in subsequent experi-
ments. Vero-WHO cells were incubated with 10 µM tomatidine or the equivalent volume of EtOH and infected 
with CHIKV-LR at MOI 0.5. Under standard infection conditions, 4.9 ± 0.0 Log infectious virus particles (8.1 
× 104 PFU/mL) were produced at 9 hpi (Fig. 1a). A comparable titer was observed for the 0.1% EtOH con-
trol (5.0 ± 0.1 Log), indicating that the solvent does not influence infectious virus particle production. In line 
with previous results on DENV and ZIKV21, tomatidine was found to exert significant antiviral activity towards 
CHIKV. In the presence of 10 µM tomatidine, the infectious virus titer was reduced to 4.4 ± 0.3 Log, which corre-
sponds to a reduction by 76.8% when compared to the EtOH control (Fig. 1a).
In order to validate these findings in a more relevant cell line for human infection, we next investigated the 
cytotoxic and antiviral potential of tomatidine in Huh7 cells (human hepatic cell line) as hepatocytes are targets 
during natural CHIKV infection25. Furthermore, like with Vero-WHO, these cells are also commonly used in 
antiviral CHIKV studies13,26–28. In our previous study on DENV, the cytotoxicity profile of tomatidine in Huh7 
cells has been determined via the MTT assay, measuring the metabolic activity of the cell via mitochondrial activ-
ity21. Since mitochondrial activity is only one of many factors that determine cell viability, we here performed two 
additional cytotoxicity assays, the ATPLite assay, which measures the cellular ATP level and a trypan blue staining 
to detect the number of viable cells after tomatidine treatment. A dose-dependent decrease in ATP levels with 
increasing tomatidine concentrations was seen. The highest non-toxic tomatidine concentration was 20 µM and 
the CC50 value was defined as 156 µM (Supplementary Fig. S1b). The highest non-toxic concentration is slightly 
lower compared to the previously reported results for the MTT assay on Huh7 cells, where the highest non-toxic 
tomatidine concentration was defined as 30 µM21. The trypan blue staining revealed a significant reduction in 
total cell number at tomatidine concentrations >10 µM (Supplementary Fig. S1c). Based on the above described 
results, we defined 10 µM as the maximal non-toxic dose of tomatidine, in which metabolic activity, ATP levels 
and total cell numbers were not significantly changed. To investigate the potential additional cytopathic effect 
of CHIKV on the viability of tomatidine-treated-Huh7 cells, we next assessed the viability of Huh7 cells in the 
presence of 10 µM tomatidine under infection conditions via the MTS assay. As displayed in Supplementary 
Fig. S1d, where the results were normalized to a non-infected, non-treated control, infection with CHIKV at 
MOI 1 did not have an additional cytopathic effect on the Huh7 cells. Compared to the non-infected, non-treated 
control, no changes in cell viability were observed upon infection in the presence or absence of 10 µM tomatidine 
(Supplementary Fig. S1d). Hence, we decided to use 10 µM tomatidine as the highest concentration for all subse-
quent experiments in Huh7 cells.
To test the antiviral activity of tomatidine in Huh7 cells, cells were incubated with increasing concentrations 
of tomatidine (0.1 to 10 µM) at the time of infection with CHIKV-LR (MOI 1). On average 4.8 ± 0.2 and 4.9 ± 0.2 
Log progeny infectious particles were produced for non-treated and EtOH-treated infection samples, respectively 
(Fig. 1b). Hence, the presence of EtOH did not influence the production of progeny infectious virus particles. 
Importantly, a dose-dependent decrease in the production of infectious CHIKV particles was observed in the 
presence of increasing tomatidine concentrations (Fig. 1b,c). In the presence of 10 µM tomatidine, 3.6 ± 0.2 Log 
infectious particles were produced, which corresponds to a 95.5% reduction in virus titer when compared to the 
EtOH control (Fig. 1b,c). Next, the EC50 and EC90 values (i.e. corresponding to 50% and 90% reduction in viral 
titer, respectively) were calculated by non-linear regression analysis. An EC50 and EC90 value of 1.3 µM and 
3.5 µM was found, respectively (Fig. 1c). In order to calculate the SI, the CC50 value determined via ATPLite 
assay (156 µM) was divided by the EC50 value. Hence, the SI of tomatidine towards CHIKV infection in Huh7 
cells is 120.
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In order to further validate the antiviral effect of tomatidine towards CHIKV, we next evaluated its antivi-
ral potential in two other human cell lines relevant during natural CHIKV infection, namely, skin fibroblast 
HFF-1 cells and bone osteosarcoma U2OS cells28–30. Similar to above, we again first determined the cytotoxic 
potential of tomatidine in both cell lines via the ATPLite assay. In both cell lines, a dose-dependent cytotoxic 
effect was observed, with a CC50 value of 239 µM in HFF-1 cells and 255 µM in U2OS cells (Supplementary 
Fig. S2a,b). Thereafter, we performed infection experiments at MOI 5 for HFF-1 cells and MOI 1 for U2OS cells 
in the presence of increasing tomatidine concentrations (0.5 to 10 µM) as described for the Huh7 cells. A higher 
MOI was used for HFF-1 cells given the relative lower permissiveness of these cells to CHIKV. In HFF-1 cells, a 
dose-dependent decrease in the number of infectious CHIKV particles was seen with increasing concentrations 
of tomatidine, with an EC50 value of 2.3 µM and a SI of 104 (Supplementary Fig. S2c). A similar pattern was 
observed in U2OS cells and led to an EC50 value of 3.9 µM and a SI of 65 (Supplementary Fig. S2d). Altogether, 
tomatidine exerts a significant antiviral effect towards CHIKV in all cell lines tested, the strongest effect being 
measured in Huh7 cells.
Figure 1. Tomatidine reduces the production of infectious CHIKV particles. (a) Antiviral effect of tomatidine on 
Vero-WHO cells infected with CHIKV-LR at MOI 0.5. Supernatants were collected 9 hpi. (b–f) Huh7 cells were 
infected with distinct CHIKV strains at MOI 1 in presence of increasing concentrations of tomatidine or naringenin 
or the equivalent volume of EtOH. Supernatants were collected at 9 hpi. (b,c) CHIKV-LR OPY1, (d) CHIKV-LR 
OPY1 and naringenin (e) CHIKV strain 99659, (f) CHIKV strain S27. In all experiments data is represented as 
mean ± SEM from three independent experiments and differences were assessed with Student’s t-test.
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To compare the antiviral efficacy of tomatidine to another antiviral compound under our experimental set-
tings, we next performed an antiviral study with naringenin, a natural flavonoid that has been reported to have 
potent antiviral activity towards CHIKV by Ahmadi et al. in 201624. To this end, infection experiments were per-
formed in Huh7 cells using four different naringenin concentrations (20–150 µM) to determine the approximate 
EC50 value. At these concentrations, no cytotoxic effect was measured via the ATPLite assay (Supplementary 
Fig. S3). At the highest naringenin concentration tested, virus particle production was reduced by 77.6% (4.7 ± 0.3 
Log for the EtOH control to 4.1 ± 0.2 Log in treated cells) (Fig. 1d). The approximate EC50 value for naringenin 
surrounds 40 µM. At this concentration, the CHIKV titer is reduced from 4.9 Log PFU (EtOH control) to 4.6 Log 
PFU, which corresponds to a reduction by 47%. Hence, in our experimental setup using Huh7 cells, tomatidine is 
more efficacious at lower concentrations than naringenin.
Next, we tested the antiviral effect of tomatidine towards CHIKV strains from other genotypes, namely the 
originally isolated African (S27) strain from 1953 and a recently isolated Asian CHIKV genotype (99659) in Huh7 
cells31,32. For both strains, a strong dose-dependent decrease in virus particle production was observed (Fig. 1e,f). 
For the Asian strain, the EC50 and EC90 values were 2.0 µM and 3.7 µM, respectively (Fig. 1e). A slightly lower 
potency was observed towards the African strain, with EC50 and EC90 values of 3.8 µM and 13.8 µM, respec-
tively (Fig. 1f). The respective SI was 78 for the Asian strain and 41.1 for the African strain. Altogether, the above 
described results demonstrate a potent, dose-dependent antiviral activity of tomatidine towards three distinct 
CHIKV genotypes in Huh7 cells with comparable EC50 and EC90 values.
Tomatidine has no direct virucidal effect on the CHIKV particle. To test whether the potent anti-
viral activity of tomatidine towards CHIKV is due to a direct virucidal effect of the compound on the CHIKV 
particle, 10 µM tomatidine was incubated with 2.5×105 PFU of CHIKV either at room temperature or 37 °C 
for 2 h. Subsequently, the number of residual infectious CHIKV particles were determined via plaque assay 
on Vero-WHO cells. The lowest sample dilution used in the plaque assay was 1:10, which corresponds to final 
tomatidine concentration of 1 µM. At this concentration, we did not detect an antiviral effect of tomatidine in 
Vero-WHO cells (Supplementary Fig. S4) and therefore we can use the plaque assay on Vero-WHO cells as a 
readout for virucidal activity. Importantly, incubation of tomatidine with CHIKV alone had no effect on the 
infectious titer in comparison to the EtOH control (Fig. 2). Thus, the antiviral effect of tomatidine is not owed to 
a direct virucidal effect on the CHIKV particle.
Tomatidine reduces CHIKV infection when added up to 6 h post-infection. To gain a better under-
standing of the kinetics of the antiviral activity of tomatidine, we next performed a time-of-drug-addition exper-
iment. To this end, Huh7 cells were treated with 10 µM tomatidine pre-, during or post-infection (Fig. 3a). For 
the pre-treatment conditions, Huh7 cells were incubated with tomatidine for 2 or 1 h before infection. Thereafter, 
cells were washed to remove tomatidine and infection was initiated. In the during condition, tomatidine was 
added to the cells at the time of infection. At 2 hpi, inoculum was removed, cells were washed extensively and 
fresh medium without tomatidine was added. In case of the post-treatment conditions, tomatidine was added to 
the infected Huh7 cells at 2, 3, 4, 6, 7 or 8 hpi. For all conditions, cells were infected at MOI 1 and supernatants 
were collected at 9 hpi. Each time-point included a corresponding EtOH control. Whereas for the pre- and during 
conditions tomatidine did not have any inhibitory effect on progeny infectious virus titers, a significant reduction 
in infectious particle production was seen when the compound was added at post-infection conditions and up to 
6 hpi (Fig. 3b). The strongest effect was observed at the 2 hpi treatment, with a reduction in infectious virus titer 
by 93.7% when compared to the corresponding EtOH control.
Figure 2. Tomatidine has no direct virucidal effect on CHIKV particles. 2.5 × 105 PFU of CHIKV-LR was 
incubated with 10 μM tomatidine for 2 h at room temperature (RT) or 37 °C. The infectious titer was determined 
by plaque assay on Vero-WHO cells. Data is represented as mean ± SEM from three independent experiments 
and differences were assessed with Student’s t-test.
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We next investigated whether tomatidine also has an effect on the production of genome-equivalent CHIKV 
copies (GEC) secreted by infected Huh7 cells. Hereto, Huh7 cells were infected with CHIKV-LR at MOI 1 and 
treated with 10 µM tomatidine or EtOH at the time of infection. At 9 hpi, the number of GEC was determined. 
For the non-treated and EtOH control, 6.8 ± 0.2 and 6.9 ± 0.1 Log GEC were detected, respectively (Fig. 4a). In 
the presence of tomatidine, the number of secreted GEC was reduced to 5.5 ± 0.2 Log GEC (corresponding to a 
95.5% reduction) when compared to the EtOH control (Fig. 4a). Subsequent determination of the infectious titer 
and calculation of the GEC to PFU ratio revealed that there are no significant differences between the ratios in the 
absence and presence of tomatidine. In presence of EtOH, the ratio was determined as 356 ± 76 and for tomati-
dine a ratio of 334 ± 72 was calculated (Fig. 4b). Thus, the antiviral effect of tomatidine is related to a reduction 
in the overall production of GEC rather than specifically interfering with the infectious properties of secreted 
viruses.
Figure 3. Tomatidine reduces CHIKV infection when added up to 6 hpi. (a) Outline of the experimental 
set-up. (b) Huh7 cells were infected with CHIKV-LR at MOI 1 and treated with 10 µM tomatidine or the 
equivalent volume of EtOH prior to infection (−2 or −1 h), during infection or at different times post-infection 
(2 to 8 hpi). Supernatants were collected 9 hpi. Data is represented as mean ± SEM from four independent 
experiments and differences were assessed with Student’s t-test.
Figure 4. Tomatidine has no effect on the specific infectivity of CHIKV. (a) Huh7 cells were infected with 
CHIKV-LR at MOI 1 and treated with 10 µM tomatidine or the equivalent volume of EtOH at the time of 
infection. Supernatants were collected at 9 hpi and RT-qPCR was performed to determine GEC/mL. (b) Ratio of 
GEC presented in (a) and corresponding PFU determined via plaque assay. Data is represented as mean ± SEM 
from three independent experiments and differences were assessed with Student’s t-test.
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Tomatidine reduces CHIKV infection in Huh7 cells. Based on the findings that tomatidine predomi-
nantly acts between 2 and 6 hpi, we next investigated whether tomatidine influences the expression of the CHIKV 
E2-protein at the cell surface of infected Huh7 cells via flow cytometry. Huh7 cells were infected with CHIKV-LR 
at MOI 1 and treated with tomatidine or EtOH at the time of infection. In infected cells, the CHIKV E2-protein 
is translocated to the endoplasmatic reticulum and processed during transit through the secretory pathway prior 
to expression at the cell surface. Thus, changes within the expression level of E2 at the cell surface in the presence 
of tomatidine may be indicative for an inhibition of the E2 processing and transport to the cell surface. At 9 hpi, 
2.8 ± 0.3% E2-positive cells were observed following infection at MOI 1 (Fig. 5a). At 16 hpi, i.e. after approx-
imately two rounds of CHIKV replication, the number of E2-positive cells increased to 25.4 ± 5.2% (Fig. 5a). 
Comparable numbers were seen for the corresponding EtOH controls. Importantly, in the presence of tomatidine, 
the number of E2-positive cells was reduced to 0.8 ± 0.3% and 9.1 ± 2.0% at 9 and 16 hpi, respectively, which 
corresponds to a reduction by 78.8% (9 hpi) and 67.2% (16 hpi) compared to the EtOH control. Intriguingly, 
even though a clear reduction in the number of E2-positive cells was seen, a minor effect on the mean fluores-
cent intensity (MFI) within the E2-positive population was observed (Fig. 5b). At MOI 5, the same pattern was 
observed (Supplementary Fig. S5). Here, the percentage of infection was reduced by 75.6% (9 hpi) and 53.8% (16 
hpi) in the presence of tomatidine, whereas the effect on the MFI was again minor (Supplementary Fig. S5a,b). 
Comparable results were obtained when cells were permeabilized to allow both intracellular and extracellular 
staining of E2 (Supplementary Fig. S6a–c). Furthermore, based on the fluorescence intensity measured in both 
experimental conditions, the vast majority of E2 is expressed at the cell surface at 9 hpi. Taken together, the above 
results imply that once infection is established, the expression and transport of the E2 protein to the cell surface 
is mostly unaffected.
Antiviral activity of tomatidine is sustained for multiple rounds of cHiKV replication. During 
natural infection, the virus replicates continuously within the body. Therefore, we aimed to investigate for how 
long tomatidine is able to exert its antiviral activity. To this end, we infected cells with CHIKV-LR at MOI 0.01 in 
the presence of tomatidine and determined progeny virus particle production at 24 and 48 hpi. These time-points 
correspond to approximately three and six rounds of CHIKV replication, respectively. For samples collected at 
48 hpi, the medium remained unchanged or was replaced with fresh medium containing 10 µM tomatidine or 
EtOH at 24 hpi. Figure 6 reveals that tomatidine reduces CHIKV particle production for at least three rounds of 
replication. The viral titer of the non-treated samples reached 5.3 ± 0.2 Log progeny infectious particles at 24 hpi 
(Fig. 6). A similar titer was seen for the EtOH control. Tomatidine treatment lead to a reduction in CHIKV titer 
by 87.8% to 4.3 ± 0.3 Log compared to the EtOH control (Fig. 6) at 24 hpi. At 48 hpi, no significant difference in 
infectious virus particle production could be observed between cells treated with EtOH (7.2 ± 0.3 Log) or tomati-
dine (6.4 ± 0.3 Log) (Fig. 6). Nevertheless, there was still a trend towards a reduction in virus titer in the presence 
of tomatidine. Importantly, replenishment of tomatidine at 24 hpi did lead to a significant reduction in infectious 
titer (95.8%) at 48 h (Fig. 6). Similar results were obtained at MOI 0.1, hence at a ten-times higher virus concen-
tration (Supplementary Fig. S7). Here, tomatidine reduced the CHIKV titer by 85.7% at 24 hpi and by 90.6% at 48 
hpi with tomatidine replenishment. Altogether, this suggests that tomatidine is able to effectively control CHIKV 
replication for at least three replication cycles independent of the viral load. To achieve protection at 48 hpi, a 
replenishment of tomatidine is necessary.
tomatidine derivatives solasodine and sarsasapogenin inhibit cHiKV infection. Testing of 
structural derivatives of antiviral compounds is a common strategy to enhance their antiviral activity and/or 
Figure 5. Tomatidine reduces the cell surface expression of the CHIKV E2 protein. Huh7 cells were infected 
with CHIKV-LR at MOI 1 and treated with 10 µM tomatidine or the equivalent amount of EtOH at the time of 
infection. (a) Cells were collected, fixed and stained for CHIKV E2 protein on the cell surface at 9 and 16 hpi. 
(b) Relative fold changes in MFI in the presence of tomatidine compared to the EtOH control at 9 and 16 hpi. 
Data is represented as mean ± SEM from three independent experiments and differences were assessed with 
Student’s t-test.
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can identify the structural regions of the compound that are relevant for the antiviral activity. We tested three 
commercially available tomatidine derivatives: tomatine, solasodine and sarsasapogenin for their antiviral effect 
towards CHIKV-LR in Huh7 cells. The structure of tomatidine and the above derivatives is depicted in Fig. 7a. 
Based on the cytotoxicity profile (Supplementary Fig. S8a–c), we used a concentration of 5, 5 and 20 µM for 
tomatine, solasodine and sarsasapogenin in the infectivity assays, respectively. Figure 7b shows that the infectious 
titer of the non-treated control is 5.02 Log PFU. The EtOH control for each compound showed comparable titers. 
Unexpectedly however, in presence of CHIKV, tomatine concentrations of 5, 2 and 1 µM lead to a strong cyto-
toxic effect with extensive cell death through which we were not able to analyze its true antiviral effect. Even at 2 
and 1 µM tomatine extensive cell death was observed and therefore we excluded tomatine from further analysis. 
Solasodine and sarsasapogenin treatment lead to a significant, yet less potent reduction in infectious particle 
production when compared to the tomatidine control. While for tomatidine-treated cells a reduction to 3.8 Log 
PFU was observed (92.5% reduction compared to EtOH control), solasodine- and sarsasapogenin-treated cells 
reduced virus progeny production to 4.5 and 4.2 Log (Fig. 7b). This corresponds to a reduction by 82.5% and 
76.4% compared to the EtOH control, respectively. Thus, within the group of tested tomatidine derivatives, toma-
tidine remains the most potent antiviral compound towards CHIKV.
Discussion
We have identified the natural steroidal alkaloid tomatidine as a novel antiviral compound towards CHIKV. 
Tomatidine potently inhibited infection of three different CHIKV genotypes in Huh7 cells. The most potent 
antiviral effect can be seen towards the CHIKV La Reunion strain, which belongs to the CHIKV East/Central/
South African genotype with an EC50 value of 1.3 µM and an SI of 120. For the other tested genotypes, an ancient 
African genotype and a more recent Asian genotype, EC50 values of 3.8 µM and 2.0 µM were determined, respec-
tively. The corresponding SI are 41.1 (African strain) and 78 (Asian genotype). A direct virucidal effect of toma-
tidine on the CHIKV particle was excluded. Subsequent time-of-addition experiments demonstrate that the 
antiviral effect is caused at post-infection conditions and is maintained upon addition of the compound until 6 
hpi. Tomatidine did not alter the specific infectivity of CHIKV. Moreover, we showed that tomatidine is able to 
control CHIKV replication for at least 3 rounds of replication. When testing commercially available structural 
derivatives of tomatidine, i.e. solasodine and sarsasapogenin, consistent yet slightly less potent antiviral effects 
towards CHIKV were seen.
The SI is a commonly used parameter in antiviral research to evaluate the specificity of antiviral compounds. 
The SI index is an adequate general parameter to define the specificity of newly discovered antivirals, however it 
only gives limited information as it is dependent on the experimental setup, i.e. the MOI and the cell type used. 
Compared to other reported antiviral compounds towards CHIKV, the SI of tomatidine shows high specificity 
and potency11,13,33,34. Therefore, tomatidine is a promising antiviral compound to treat CHIKV infection.
At the highest non-toxic concentration of tomatidine (10 µM), a 20-fold reduction in viral progeny was 
observed. Tomatidine was found to act at post-infection conditions as no antiviral effect was observed for the 
pre- and during infection treatments. Furthermore, a clear (~4-fold) reduction in the number of E2-positive cells 
in the presence of tomatidine was seen. However, this cannot completely explain the 20-fold reduction observed 
in the secretion of virus particles, especially since the cells that were infected with CHIKV in presence of toma-
tidine had substantial expression levels of viral E2. We therefore hypothesize that tomatidine interferes with 
multiple processes in the replicative cycle of CHIKV. First, infection is aborted after entry and membrane fusion 
Figure 6. Anti-CHIKV activity of tomatidine is observed for multiple replication cycles. Huh7 cells were 
infected with CHIKV MOI 0.01 and treated with 10 µM tomatidine at the time of infection. Supernatants were 
collected 24 and 48 hpi. Alternatively, the medium was replaced by fresh medium containing 10 µM tomatidine 
or EtOH after 24 h. Data is represented as mean ± SEM from three independent experiments and differences 
were assessed with Student’s t-test.
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but prior to E2 protein translation and transportation to the cell surface. Second, tomatidine may act on nucle-
ocapsid formation, virion assembly and/or budding of progeny virions. The mode of action of tomatidine might 
be dependent on the concentration of the compound within the cells. Future studies should reveal the precise 
mode of action of tomatidine and whether it acts as a direct or host-directed antiviral compound in controlling 
CHIKV infection.
Recently, we have also demonstrated that tomatidine has a potent antiviral activity towards all four DENV 
serotypes and ZIKV but not WNV. Intriguingly, all three viruses belong to the flavivirus genus of the family of 
flaviviridae, and CHIKV, which is a member of the alphavirus genus of the family togaviridae, is much more 
distantly related to DENV than DENV to WNV. Interestingly, however, by comparing the results for DENV and 
CHIKV, similarities can be found. First, for both viruses the most potent antiviral effect is seen when tomatidine is 
added at 2 hpi. This suggests that for both viruses, an early but post-binding and entry step of the virus replication 
cycle is targeted by tomatidine. For CHIKV, tomatidine only showed effective protection for the post-treatment 
condition, whereas for DENV the pre and during treatment also showed a clear, albeit less potent, antiviral effect 
compared to the post-treatment. Therefore, tomatidine may target an additional, early step of the virus replication 
cycle in DENV infection. Alternatively, the difference between pre- and during treatment condition may also be 
explained by the differences in the replication time of DENV (24 hours) and CHIKV (8 hours). In this context, 
tomatidine may be internalized too slowly to exert its antiviral effect towards CHIKV, but not towards DENV. 
Furthermore, for both viruses the number of cells expressing the viral envelope protein revealed a potent, but 
much less pronounced antiviral effect compared to the effect seen on the viral particle production again pointing 
towards a shared mechanism. The question why we do not see an antiviral effect towards WNV, a virus that is 
much more closely related to DENV and ZIKV, however, remains to be elucidated.
The two out of three commercially available derivatives of tomatidine, solasodine and sarsasapogenin exhib-
ited a constant but less potent antiviral activity compared to tomatidine. These results imply that structural groups 
altered in the derivatives may be in fact important determinants of tomatidine activity. Solasodine has an addi-
tional double bond within the steroidal ring structure, whereas sarsasapogenin is missing the nitrogen of the 
spiroaminoketal group. Previous studies on the antibacterial properties of tomatidine show that the two extrem-
ities of tomatidine, namely the beta-hydroxyl group and the spiroaminoketal group including the basic nitrogen, 
are responsible for its antibacterial activity35. The remaining steroidal rings serve as a structural scaffold. Since 
Figure 7. Solasodine and sarsasapogenin show potent antiviral activity towards CHIKV. (a) Structures of 
tomatidine, tomatine, solasodine and sarsasapogenin. (b) Antiviral effect of tomatidine and its derivatives 
on infectious particle production following CHIKV-LR infection at MOI 1. Supernatants were collected 9 
hpi. Corresponding treatment concentrations of different compounds: Tomatidine 10 µM, solasodine 5 µM, 
sarsasapogenin 20 µM. Data is represented as mean ± SEM from three independent experiments except for 
sarsasapogenin, where four independent experiments were performed, and the mean ± SEM from all four 
experiments is displayed. Differences were assessed with Student’s t-test.
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sarsasapogenin, which misses the basic nitrogen of tomatidine, shows less potent antiviral activity compared to 
solasodine and tomatidne, the basic nitrogen in the aminoketal group may be important for the antiviral activity 
of tomatidine towards CHIKV. Furthermore, and in line with Chagnon et al., the double bond within the steroid 
ring scaffold does not seem to change the antiviral potential of tomatidine. Altogether, these findings suggests that 
the basic nitrogen may be partly responsible for the antiviral activity of tomatidine. Whether the beta-hydroxyl 
group also relevant for tomatidine to exert its antiviral effect remains to be evaluated.
In order to further evaluate the potential of tomatidine as an antiviral drug, other important factors includ-
ing the pharmacokinetic profile, as well as the protein-binding properties of tomatidine have to be taken into 
account. Unfortunately, to date literature on those aspects is scarce. Tomatidine has been used in several in vivo 
mouse studies and no toxicity was observed up to a concentration of 50 mg/kg19,36–40. Only one study meas-
ured the steady-state tomatidine plasma levels and revealed a plasma concentration of 287 ng tomatidine per 
mL after 2 month of oral treatment with 0.05% (w/w) tomatidine added to standard chow36. Whereas this study 
gives some insight into the distribution of tomatidine, further studies are needed to give an in-depth insight 
into the stability and biodistribution of tomatidine in vivo. With regard to protein-binding properties of tomati-
dine, there is no literature available that directly demonstrates binding of tomatidine to viral or cellular proteins. 
Nevertheless, numerous papers have demonstrated the ability of tomatidine to modulate different bacterial or 
host-cell pathways14,15,40,41. As an example, a study by Boulet et al. in 2017, demonstrated that tomatidine inhibits 
the Staphylococcus aureus ATP Synthase subunit C to exert its antibacterial properties17. Moreover, tomatidine 
has been shown to inhibit cellular ATF4 expression, which leads to a reduction in age-related muscle weakness 
and atrophy36. The ability of tomatidine to control ATF4 expression has also been shown by our recent publication 
from 2019, though this did not explain the antiviral activity of tomatidine towards DENV21. Collectively, despite 
the numerous functions of tomatidine further studies characterizing the pharmacokinetic profile as well as the 
protein binding properties of tomatidine are needed to further evaluate tomatidine as a potent antiviral drug.
Our current in vitro findings identify tomatidine as a promising antiviral compound to treat CHIKV infection. 
Toxicity profiles, time-of-addition studies and durability experiments demonstrate a potent and robust antiviral 
activity. Tomatidine shows a potent antiviral effect when added up to 6 hpi, which is rare among the currently 
identified potential antiviral compounds towards CHIKV. Nevertheless, further studies regarding the efficacy in 
vivo and the pharmacokinetics of tomatidine are essential to further evaluate its potential as an antiviral com-
pound. Aside from the ability of tomatidine to inhibit CHKV infection, its reported anti-inflammatory activities 
as well as interferon-stimulating effects may also be of importance as this may alleviate the symptoms associated 
with CHIKV fever15,38.
Methods
cell culture. The human hepatocarcinoma cell line Huh7 (JCRB0403), kindly provided by Tonya Colpitts 
(University of South Carolina) and the human bone osteosarcoma cell line U2OS (ATCC HTB-96) were main-
tained in Dulbecco’s minimal essential medium (DMEM) Glutamax (Gibco, The Netherlands) supplemented 
with 10% FBS (Lonza, Basel, Switzerland), 100 U/mL penicillin and 100 mg/mL streptomycin (PAA Laboratories, 
Pasching, Austria). The human skin fibroblast cell line HFF-1 (ATCC SCRC-1041) was maintained as described 
above, with the exception that the medium was supplemented with 15% FBS. Vero-WHO cells, renal cells derived 
from the African Green monkey, (WHO Reference Cell Bank 10–87, ATCC CCL-81) were maintained in DMEM 
containing 5% FBS, 100 U/mL penicillin and 100 mg/mL streptomycin. All cell lines were cultured at 37 °C and 
5% CO2.
Virus stocks and titration. CHIKV (La Reunion OPY1) was a kind gift from A. Merits (University of Tartu, 
Estonia). CHIKV strain S27 was kindly provided by S. Guenther, Bernhard-Nocht-Institute for Tropical Medicine 
and was isolated in 1953 in Tanzania. CHIKV strain 99659, an Asian genotype isolated in 2014 from the British 
Virgin Islands in the Caribbean was a kind gift from M. Diamond (Washington University, School of Medicine). 
For virus production, Vero-WHO cells were infected at a multiplicity of infection (MOI) of 0.01 and progeny viri-
ons were harvested at 46 h post-infection (hpi). Subsequently, the virus-containing supernatants were centrifuged 
to clarify from cell debris, aliquoted and stored at −80 °C. Infectious virus titers were determined by plaque assay 
on Vero-WHO cells and defined as the number of plaque forming units (PFU) per mL. Briefly, Vero-WHO cells 
were seeded at a density of 13×104 cells/well in a 12-well plate. At 24 h post-seeding, cells were infected with 10-fold 
serial dilutions of the sample in duplo. At 2 hpi, wells were overlaid with 1% seaplaque agarose (Lonza, Swiss) pre-
pared in 2x MEM. Plaques were counted at 44 hpi. The number of genome-equivalent copies (GEC) per mL was 
determined via Q-RT-PCR using a StepOne Real-Time PCR instrument (Applied Biosystems, Foster City, CA, 
USA), as described previously42. RNA extraction was performed using a QIAmp viral RNA mini kit (QIAGEN, 
Venlo, The Netherlands). cDNA synthesis from viral RNA was performed using Omniscript (QIAGEN) and the 
primers 5′AGCTCCGCGTCCTTTACCA-3′ (forward) and 5′-GCCAAATTGTCCTGGTCTTCCT-3′ (reverse). 
For qPCR the TaqMan probe 5′-FAMCACTGTAACTGCCTATGCAAACGGCGAC-TAMRA-3′ (Eurogentec, 
Maastricht, The Netherlands) was used. DNA amplification was performed for 40 cycles of 15 s at 95 °C and 60 s at 
60 °C. The number of GEC was determined using a standard curve (correlation coefficient >0.995) of a quantified 
cDNA plasmid containing the CHIKV E1 sequences (pCHIKV-LS3 1B).
chemicals. Tomatidine hydrochloride, solasodine, and sarsasapogenin were purchased from Sigma Aldrich 
(St. Louis, Missouri, USA) and dissolved in absolute ethanol (EtOH) to a final concentration of 5 mM. Tomatine 
(Santa Cruz Biotechnology) was prepared in absolute EtOH to a final concentration of 2.5 mM. Naringenin was 
purchased from Santa Cruz Biotechnology (Dallas, Texas, USA) and dissolved in absolute EtOH to a final concen-
tration of 50 mM. All stock solutions were stored at −20 °C and used for a maximum of 3 months. The final EtOH 
concentration was below 0.1% in all infection experiments.
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cytotoxicity assay. The cytotoxicity of tomatine, tomatidine, solasodine and sarsasapogenin was deter-
mined in vitro via an ATPLite Luminescence Detection assay system. Huh7, U2OS, HFF-1 or Vero-WHO cells 
were seeded in a white polystyrene 96-well plate at a density of 8.0×103. At 24 h post-seeding, cells were treated 
with increasing concentrations of the different compounds ranging from 1 to 500 µM. At 24 h post-treatment, 
50 µL mammalian cell lysis solution was added per well and the plate was incubated for 5 min at room tempera-
ture on an orbital shaker. Subsequently, 50 µL substrate solution was added to wells and the plate was incubated 
for 5 min, as before. Then, the plate was incubated for 10 min in the dark. Luminescence was measured with a 




⁎Cytotoxicity% (Abs sample) (Abs blank)
(Abs negative control) (Abs blank)
100
For tomatidine, cytotoxicity in Huh7 cells was also measured via determining the total cell number. To this 
end, Huh7 cells were seeded in a 12-well plate at a density of 1.2 × 105 cells/well. At 24 h post-treatment, cells 
were trypsinized with 1x Trypsin/EDTA (Gibco), stained with trypan blue (Sigma) and counted manually using 
a Buerker counting chamber depth 0.100 mm (Marienfeld, Lauda-Koenigshofen, Germany).
Additionally, the cytotoxic effect at the highest non-toxic concentration of tomatidine (10 µM) was evalu-
ated in Huh7 cells in the presence of CHIKV via the CellTiter 96 Aqueous Non-Radioactive Cell Proliferation 
Assay (MTS assay). To this end, Huh7 cells were seeded in a 96-well plate as described above and infected with 
CHIKV-LR at MOI 1. At the time of infection, cells were treated with 10 µM tomatidine or the equivalent volume 
of EtOH. At 24 h post infection, 20 µL MTS/PMS solution was added per well and the plate was further incubated 
for 2 h at 37 °C. Subsequently, 10% formaldehyde was added to inactivate the virus and the absorbance was meas-
ured at 490 nm with a microplate reader. Cytotoxicity was expressed as described for the ATPLite assay. Values 
were then displayed as percentage compared to a non-infected, non-treated control.
Antiviral assays. Vero-WHO, Huh7, U2OS and HFF-1 cells were infected with CHIKV at MOI 0.5, 1 or 
5. Unless indicated otherwise, tomatidine, solasodine, sarsasapogenin or naringenin (or the equivalent vol-
ume of ethanol) were added at the time of infection. The virus inoculum was removed at 2 hpi, after which the 
cells were washed three times, and compound-containing medium was added until sample collection. For the 
time-of-addition experiments, Huh7 cells were treated with tomatidine either pre-, during or post-infection. For 
the pre-treatment, 10 µM tomatidine was added 1 or 2 h before infection, as indicated. At the time of infection, 
cells were washed three times before the addition of the virus inoculum. For the during condition, tomatidine 
was added together with the virus inoculum and was present for only for 2 h. For the post-treatment condition, 
tomatidine was added at 1, 2, 4, 6, 7 and 8 hpi. In all experiments, the virus inoculum was removed after two hours 
and the supernatant was collected at 9 or 16 hpi.
Virucidal effect. CHIKV-LR (2.5×105 PFU) was incubated in the presence or absence of 10 µM tomatidine 
or the equivalent volume of ethanol at room temperature or 37 °C for 2 h in a total volume of 250 µL. Subsequently, 
the infectious virus titer was determined via plaque assay.
flow cytometry. Huh7 cells were trypsinized with 1x Trypsin/EDTA (Gibco) and fixed with 2% para-
formaldehyde. After fixation, the cells were stained with a rabbit anti-E2-stem antibody (obtained from G. 
Pijlman, Wageningen University, Wageningen, The Netherlands) diluted 1:1000 and a AF647 conjugated chicken 
anti-rabbit antibody diluted 1:300 (Life Technologies, Carlsbad, California, USA). Flow cytometry analysis was 
performed with a FACSCalibur cytometer (BD Biosciences) and analysis was performed via Kaluza 1.1.
Durability study. Huh7 cells were infected with CHIKV-LR OPY1 at MOI 0.01 or MOI 0.1 and treated with 
10 µM tomatidine or EtOH, as described in the antiviral assay section. Supernatants were collected at 24 or 48 
hpi. For the samples collected at 48 hpi, the medium remained unchanged after infection or was replaced by fresh 
complete medium containing 10 µM tomatidine or EtOH at 24 hpi. Virus titer was determined via plaque assay.
Statistical analysis. The EC50 and EC90 values represent the tomatidine concentration that reduces virus 
particle production by 50 or 90%, respectively. The CC50 and CC90 values, represent the tomatidine concentra-
tion that causes 50 and 90% cytotoxicity, respectively. The corresponding dose-response curves were fitted by 
non-linear regression analysis using a sigmoidal model. The calculated selectivity index (SI) represents the ratio 
of CC50 to EC50. All data was analyzed with GraphPad Prism (La Jolla, CA, USA) and data are presented as mean 
± SEM. Statistical differences were evaluated via Student’s t-test, a value of p ≤ 0.05 was considered significant, 
with *p ≤ 0.05, ** p ≤ 0.01 and *** p ≤ 0.001.
Data availability
The data described in this study are available from the corresponding author upon request.
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